Overview

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women

Status:
Recruiting

Trial end date:
2023-05-18

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase iii clinical study evaluating the efficacy and safety of FCN- 437c in combination with fluvestrant ± goseraline versus placebo in combination with fluvestrant ± goseraline in women with HR+ and HER2- advanced breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Ahon Pharmaceutical Co., Ltd.

Treatments:

Fulvestrant
Goserelin